Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Foresee Pharmaceuticals announced the appointment of Dr. Bassem Elmankabadi as Senior Vice President of Clinical Development on April 17, 2023. Dr. Elmankabadi brings over 17 years of clinical experience, previously holding leadership roles at Amgen (NASDAQ: AMGN) and FibroGen (NASDAQ: FGEN). His experience includes negotiating four Clinical Development Plans for Phase 2 and 3 studies for the company's drugs, Cudetaxestat and Pamrevlumab. Dr. Elmankabadi's background includes surgical leadership and clinical instruction at UCLA. Foresee Pharmaceuticals focuses on innovative therapies, with key products including CAMCEVI for advanced prostate cancer, approved in the U.S., Canada, and EU, as well as other promising candidates in clinical development.
Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. Senior Vice President Susan Sweeney will represent the company. The presentation will be accessible through a live webcast for media, investors, and the public, with a replay available for 90 days post-event. Amgen focuses on developing innovative human therapeutics, using advanced genetics to address serious illnesses and unmet medical needs. A biotechnology leader since 1980, Amgen is a part of the Dow Jones Industrial Average and Nasdaq-100, recognized for its sustainability and employer ranking.
Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q2 2023, payable on June 8, 2023, to stockholders of record by May 18, 2023. This announcement highlights Amgen's commitment to returning value to shareholders while reflecting its strong market position. As a prominent player in biotechnology, Amgen's focus on innovative therapeutics aligns with its strategy of addressing high unmet medical needs. The company was recognized in 2022 for its commitment to sustainability and was named one of the 'World's Best Employers' by Forbes.
Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference on March 8, 2023, at 11:10 a.m. ET. The presentation will feature Murdo Gordon and Peter H. Griffith, executive vice presidents at Amgen. The event will be accessible via a live webcast for media, investors, and the public. Interested parties can find details on Amgen’s website under Investors, with the presentation archived for 90 days post-event. Amgen has been a pioneer in biotechnology since 1980, focusing on innovative therapies for serious illnesses and is recognized as one of the Dow Jones Industrial Average companies.
Amgen recently announced significant findings regarding its cholesterol-lowering therapies, Repatha (evolocumab) and olpasiran, at the American College of Cardiology's annual session (March 4-6, 2023, New Orleans). Data from the Phase 3 FOURIER and FOURIER-OLE studies showed that earlier and extended use of Repatha leads to a reduction in total cardiovascular events among patients with atherosclerotic cardiovascular disease (ASCVD). Furthermore, the Phase 2 OCEAN(a)-DOSE study demonstrated that olpasiran significantly reduces lipoprotein(a) levels regardless of baseline concentrations. Amgen also initiated the first LDL-C Action Summit to address challenges in cardiovascular care.
Amgen has launched the African American Heart Study, a collaboration with the Association of Black Cardiologists and Morehouse School of Medicine. This observational study aims to investigate the link between Lipoprotein(a) levels and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American participants across the U.S. Cardiovascular disease poses a heightened risk to African Americans, who are 30% more likely to die from heart disease than non-Hispanic whites. The study seeks to address the underrepresentation of African Americans in cardiovascular research and may provide insights for improving clinical trial diversity.
Amgen (NASDAQ:AMGN) is scheduled to present at the 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. ET. Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities, will lead the presentation. The event will be available via live webcast for media, investors, and the public.
Details and replay options will be found on Amgen's website under Investors. As a leading biotechnology firm, Amgen focuses on significant unmet medical needs and aims to enhance health outcomes through innovative therapies. The company is recognized in major indices, including the Dow Jones Industrial Average.
Amgen and AstraZeneca announced that the FDA has approved TEZSPIRE (tezepelumab-ekko) for self-administration in a pre-filled pen for patients aged 12 and older with severe asthma. TEZSPIRE is the only biologic without phenotype limitations for severe asthma, initially approved in December 2021. The decision was based on results from the PATHFINDER clinical trials, where 92% of participants successfully administered the treatment at home. TEZSPIRE is also approved in the EU and under review in other countries. Common adverse reactions include pharyngitis, arthralgia, and back pain. Amgen and AstraZeneca will collaborate to commercialize TEZSPIRE in North America.
Amgen recently made available the full transcript and audio replay of its 2022 fourth quarter and full year financial results webcast. This webcast showcases key developments in Amgen's business and provides insights into the company's performance. Interested parties can find the transcript and audio on Amgen's website under the Investors section. The audio will be archived for at least 90 days, allowing for convenient access to the information discussed during the event.
Amgen reported its Q4 2022 revenues at $6.8 billion, nearly unchanged from Q4 2021, with a 4% rise in product sales with 10% volume growth. For the full year, revenues reached $26.3 billion, a 1% increase, driven by a 2% rise in product sales. However, GAAP EPS fell 11% in Q4 to $3.00, despite a full-year increase of 18% to $12.11. Amgen anticipates total revenues between $26.0 billion and $27.2 billion in 2023, while excluding contributions from the acquisition of Horizon Therapeutics.